商品名：Modrenal and Vetoryl
Trilostane inhibits synthesis of cortisol in dogs. It is a competitive inhibitor of 3-beta-hydroxysteroid dehydrogenate, which will interfere with the steps that lead to cortisol secretion from the adrenal cortex. This enzyme is also involved with synthesis of aldosterone, corticosterone, and androstenedione. It also affects conversion of pregnenolone to progesterone. Therefore, these hormones also may be decreased from treatment with trilostane. It is used for pituitary-dependent hyperadrenocorticism (PDH) in dogs. Compared to mitotane, which destroys adrenocortical cells, trilostane produces
Trilostane is used to treat hypercortisolemia (hyperadrenocorticism) in dogs (Cushing’s disease). Cortisol concentrations will decrease as early as 7-10 days after initiating treatment with trilostane. It is reported to improve polyuria, polydipsia, and polyphagia in 70%-80% of dogs with PDH. Treatment with mitotane has been compared with trilostane and it has been shown that each drug, although acting through different mechanisms, produces similar survival times in dogs with PDH. Other drugs used to treat canine Cushing’s disease include mitotane (Lysodren), selegiline (Anipryl), and ketocona
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
確認犬隻與精確診斷 確認實際品牌、產品、劑型、強度／濃度、容器、量測器具、法域與標籤修訂 確認基線肝腎、生化、電解質與血液學狀態 依精確標籤安排給藥後 ACTH 刺激試驗與追蹤 確認米托坦轉換史、ACE 抑制劑、保鉀利尿劑與鉀相關治療 急病或疑似低腎上腺皮質功能時立即停藥並評估救援
DRUGAPI 劑量審查引用的獸醫官方標示（各標示只適用於其產品、物種與法域，不可互換）
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。